Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation

Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Ongoing Global Trials and Promising Candidates Like Sovleplenib Create Strong Investment and ...

The SYK inhibitor market is poised for rapid growth, driven by increased interest in addressing unmet needs in autoimmune diseases, hematological conditions, and cancer. With ongoing clinical trials ...
PharmiWeb

TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026-2030 with Focus on US, China, South Korea, Australia, and Europe - ResearchAndMarkets.com

The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering.This report tracks developments currently taking place ...